Benefits
Verbal Episodic Memory Preservation in Elderly
The Hisatsune 2016 RCT (n=39 elderly, 3 months, 1 g anserine/carnosine 3:1 daily) showed significant preservation of delayed-recall verbal episodic memory (Wechsler Memory Scale-Logical Memory delayed recall, p=0.0128). Effect specific to delayed recall (memory consolidation), not immediate working memory. Subsequent trials replicated the effect.
Brain Blood Flow Preservation
The Hisatsune 2018 sub-analysis (n=68 elderly) showed anserine/carnosine supplementation preserved prefrontal brain blood flow specifically in APOE4 carriers — a high-risk genotype for accelerated brain aging and Alzheimer's disease. APOE4 carriers showed greater benefit than non-carriers, consistent with anserine's effects on neurovascular units.
MCI / APOE4-Specific Cognitive Benefit
The Masuoka 2019 RCT (n=54 with mild cognitive impairment, 12 weeks) showed superior improvement in global Clinical Dementia Rating (gloCDR, p=0.023) vs. placebo. Effect was specifically observed in APOE4 carriers. NO significant effects on MMSE, Wechsler Memory Scale, or ADAS — benefit was selective to global CDR rating.
Inflammatory Chemokine Suppression
The Katakura 2017 RCT (n=60 healthy elderly, 3 months) showed anserine/carnosine decreased expression of CCL24 (an inflammatory chemokine) in peripheral blood mononuclear cells. This anti-inflammatory effect may underlie the cognitive benefits, since neuroinflammation is implicated in age-related cognitive decline.
Physical Capacity (Limited)
The Szczęsniak 2014 RCT showed modest improvements in BMI and 2 of 6 Senior Fitness Test scores in elderly subjects taking anserine/carnosine. Mood and cognitive benefits were also documented. Effects were promising but secondary to the trial's main cognitive focus.
Mechanism of action
Superior Buffering vs. Carnosine at Neutral pH
Anserine has higher buffering capacity than carnosine at physiological pH (7.4) due to the methyl group on histidine's imidazole ring. This allows more stable pH regulation in cells, particularly relevant for muscle and brain tissue under stress.
Resistance to Carnosinase Cleavage (Pharmacokinetic Advantage)
Carnosine is rapidly cleaved by serum carnosinase (CN1) in human blood, severely limiting bioavailability. Anserine is NOT a substrate for human carnosinase — providing greater systemic exposure when administered orally. This pharmacokinetic advantage may underlie better human cognitive trial results vs. carnosine alone.
Antioxidant and Anti-Glycation Activity
Anserine and carnosine scavenge reactive oxygen species and reactive carbonyl species (methylglyoxal, malondialdehyde) — preventing protein damage and AGE (advanced glycation endproduct) formation. This is particularly relevant for diabetes-related complications and aging-associated tissue damage.
Neurovascular Unit Protection
Animal Alzheimer's-model studies (AβPP/PSEN1dE9 mice) showed 8-week anserine treatment recovered memory deficits, improved pericyte coverage on brain endothelial cells, and reduced chronic glial neuroinflammation. Mechanism involves protecting the neurovascular unit (endothelial cells, pericytes, glial cells) — explaining the human APOE4 brain blood flow benefits.
Methylglyoxal Detoxification
Methylglyoxal is a reactive aldehyde implicated in diabetic complications and capillary leakage. Anserine acts as a sacrificial scavenger, neutralizing methylglyoxal before it damages proteins. The anti-AGE activity is mechanistically tied to this detoxification.
Clinical trials
Double-blind, randomized, placebo-controlled pilot trial in elderly volunteers. ACS group: 1.0 g anserine/carnosine (3:1 ratio) daily for 3 months. Outcomes: psychological tests including Wechsler Memory Scale-Logical Memory (WMS-LM). (Hisatsune, Kaneko, Kurashige, Cao, Satsu, Totsuka, Katakura, Imabayashi, Matsuda 2016, J Alzheimers Dis)
39 healthy elderly volunteers aged 60-78 in Tokyo area.
Significant preservation of delayed-recall verbal episodic memory (WMS-LM2) in ACS group vs. placebo (p=0.0128). NO significant effect on immediate recall (WMS-LM1), suggesting effect is specifically on memory registration/consolidation rather than short-term working memory. Established the foundational efficacy signal for anserine/carnosine cognitive benefits in healthy elderly.
Sub-analysis of MRI data and cognitive test scores from a previously-reported RCT. 68 participants aged ≥65 received ACS (750 mg anserine + 250 mg carnosine) or placebo for 12 months. Arterial spin labeling (ASL) and diffusion tensor imaging (DTI) MRI plus WMS-LM. (Hisatsune, Yoshimine, Wakana, Tanaka, Asada, Hisatsune 2018, J Alzheimers Dis)
68 participants aged ≥65 stratified by APOE genotype.
ACS preserved prefrontal brain blood flow specifically in APOE4 carriers — a high-risk genotype for accelerated brain aging and Alzheimer's disease. APOE4 carriers showed differential benefit consistent with anserine's neurovascular protective mechanism. Important sub-analysis identifying the population most likely to benefit from anserine supplementation.
Randomized, double-blind, placebo-controlled 12-week trial. 750 mg anserine + 250 mg carnosine per day (1 g total ACS) vs. placebo. Outcomes: global Clinical Dementia Rating (gloCDR), MMSE, Wechsler Memory Scale, ADAS. (Masuoka, Yoshimine, Hori, Tanaka, Asada, Abe, Hisatsune 2019, Nutrients)
54 subjects with mild cognitive impairment (MCI).
Score improvement in gloCDR superior in ACS group vs. placebo (p=0.023). NO beneficial effect detected on MMSE, Wechsler Memory Scale, or ADAS. Supports the pattern that ACS effects are selective and most robust for global cognitive function ratings rather than narrow psychometric measures.
Double-blind, randomized, placebo-controlled trial. 60 healthy elderly volunteers (30 active, 30 placebo) received 1.0 g anserine/carnosine (3:1) for 3 months. Microarray analysis and qRT-PCR of peripheral blood mononuclear cells (PBMCs) plus WMS-LM cognitive testing. (Katakura, Totsuka, Imabayashi, Matsuda, Hisatsune 2017, Nutrients)
60 healthy elderly volunteers.
Decreased PBMC expression of CCL24 (inflammatory chemokine) in ACS group (p<0.05). Verbal memory (WMS-LM) preserved in ACS group. Significant correlation between memory preservation and CCL24 suppression in subjects in their 70s — linking anti-inflammatory effects to cognitive benefits mechanistically.
About this ingredient
Anserine (β-alanyl-3-methyl-L-histidine) is an imidazole dipeptide closely related to carnosine. The methyl group on the histidine imidazole ring distinguishes anserine and provides important advantages: higher buffering capacity at neutral pH, and resistance to cleavage by human serum carnosinase (CN1), giving better systemic bioavailability than carnosine. Major dietary sources: chicken (especially chicken breast and meat extract), turkey, salmon, tuna, and other fish.
Plant sources are essentially absent. Most clinical research uses combination anserine/carnosine supplements (typically 3:1 ratio) derived from chicken meat extract. EVIDENCE: A coherent series of Japanese RCTs (Hisatsune 2016, Katakura 2017, Hisatsune 2018, Masuoka 2019) supports modest cognitive benefits in elderly and MCI populations — particularly verbal episodic memory preservation and brain blood flow maintenance, with strongest effects in APOE4 carriers.
The Szczęsniak 2014 European trial provides additional support. Mechanism (neurovascular protection, methylglyoxal scavenging, anti-AGE activity, inflammatory chemokine suppression) is well-characterized. SAFETY: Excellent — these are normal dietary constituents.
NOT a substitute for evidence-based dementia treatment; use as part of a broader cognitive health strategy. Most beneficial for healthy elderly seeking cognitive preservation, particularly APOE4 carriers.